These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 12912955)
1. Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Jakob C; Zavrski I; Heider U; Bollow M; Schulz CO; Fleissner C; Eucker J; Michael R; Hamm B; Possinger K; Sezer O Clin Cancer Res; 2003 Aug; 9(8):3047-51. PubMed ID: 12912955 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Carlson K; Larsson A; Simonsson B; Turesson I; Westin J; Ljunghall S Eur J Haematol; 1999 May; 62(5):300-6. PubMed ID: 10359057 [TBL] [Abstract][Full Text] [Related]
3. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Jakob C; Zavrski I; Heider U; Brux B; Eucker J; Langelotz C; Sinha P; Possinger K; Sezer O Eur J Haematol; 2002 Jul; 69(1):37-42. PubMed ID: 12270060 [TBL] [Abstract][Full Text] [Related]
4. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia]. Tanaka K; Shiraishi K; Sakamoto A; Jojima H; Masuchi K; Okubo Y; Tanaka M; Fuzimatsu Y; Fukahori S; Osabe S; Imamura Y; Honda J; Oizumi K Rinsho Ketsueki; 1998 Apr; 39(4):273-80. PubMed ID: 9597894 [TBL] [Abstract][Full Text] [Related]
5. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Elomaa I; Virkkunen P; Risteli L; Risteli J Br J Cancer; 1992 Aug; 66(2):337-41. PubMed ID: 1503907 [TBL] [Abstract][Full Text] [Related]
6. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Abildgaard N; Brixen K; Kristensen JE; Eriksen EF; Nielsen JL; Heickendorff L Br J Haematol; 2003 Jan; 120(2):235-42. PubMed ID: 12542480 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Fonseca R; Trendle MC; Leong T; Kyle RA; Oken MM; Kay NE; Van Ness B; Greipp PR Br J Haematol; 2000 Apr; 109(1):24-9. PubMed ID: 10848778 [TBL] [Abstract][Full Text] [Related]
8. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). Abildgaard N; Bentzen SM; Nielsen JL; Heickendorff L Br J Haematol; 1997 Jan; 96(1):103-10. PubMed ID: 9012695 [TBL] [Abstract][Full Text] [Related]
9. [Serum concentration of pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in the diagnosis of bone metastases]. Koizumi M; Yamada Y; Takiguchi T; Suzuki C; Akashi T; Nomura E; Yamashita T; Ogata E Kaku Igaku; 1996 Jan; 33(1):77-84. PubMed ID: 8819718 [TBL] [Abstract][Full Text] [Related]
10. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures. Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373 [TBL] [Abstract][Full Text] [Related]
11. Serum carboxy-terminal cross-linked telopeptide of type I collagen reflects bone metastasis in hepatocellular carcinoma. Ueno T; Hashimoto O; Sugawara H; Ogata R; Kusaba N; Torimura T; Sata M; Tanikawa K Int J Oncol; 1998 Aug; 13(2):297-303. PubMed ID: 9664125 [TBL] [Abstract][Full Text] [Related]
12. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Ebert W; Muley T; Herb KP; Schmidt-Gayk H Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610 [TBL] [Abstract][Full Text] [Related]
13. Osteolytic lesions marker in multiple myeloma. Djunic I; Elezovic I; Marinkovic M; Suvajdzic-Vukovic N; Tomin D; Jankovic G; Bila J; Antic D; Vidovic A; Neskovic B; Nikolic-Vukosavljevic D Med Oncol; 2011 Mar; 28(1):237-40. PubMed ID: 20127208 [TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Tähtelä R; Thölix E Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558 [TBL] [Abstract][Full Text] [Related]
15. Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma. Nabeya Y; Shimada H; Okazumi S; Matsubara H; Gunji Y; Suzuki T; Ochiai T Cancer; 2002 Feb; 94(4):940-9. PubMed ID: 11920462 [TBL] [Abstract][Full Text] [Related]
16. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastases in patients with prostate carcinoma. Hosoya Y; Arai K; Honda M; Sumi S; Yoshida K Eur Urol; 1997; 31(2):220-3. PubMed ID: 9076470 [TBL] [Abstract][Full Text] [Related]
17. The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients. Schütt P; Rebmann V; Brandhorst D; Wiefelspütz J; Ebeling P; Opalka B; Seeber S; Nowrousian MR; Moritz T; Grosse-Wilde H Hum Immunol; 2008 Feb; 69(2):79-87. PubMed ID: 18361931 [TBL] [Abstract][Full Text] [Related]
18. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Kylmälä T; Tammela TL; Risteli L; Risteli J; Kontturi M; Elomaa I Br J Cancer; 1995 May; 71(5):1061-4. PubMed ID: 7734300 [TBL] [Abstract][Full Text] [Related]
19. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Berruti A; Piovesan A; Torta M; Raucci CA; Gorzegno G; Paccotti P; Dogliotti L; Angeli A Br J Cancer; 1996 Jun; 73(12):1581-7. PubMed ID: 8664134 [TBL] [Abstract][Full Text] [Related]
20. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. Noguchi M; Noda S J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]